Cargando…

A Rare Case of Invasive Cribriform Carcinoma in Male Breast

Patient: Male, 58-year-old Final Diagnosis: Invasive cribriform carcinoma Symptoms: A painful and palpable enlarging breast mass Clinical Procedure: Adjuvant chemotherapy • surgery Specialty: Oncology OBJECTIVE: Rare disease BACKGROUND: Male breast cancer is a very rare disease that represents 0.6%...

Descripción completa

Detalles Bibliográficos
Autores principales: Ju, Hong, Um, Eunhae, Kim, Jae Il, Park, Ji Yeon, Lee, Ji Young, Kim, Ji-Ye, Chang, Sunhee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909612/
https://www.ncbi.nlm.nih.gov/pubmed/36739475
http://dx.doi.org/10.12659/AJCR.938939
Descripción
Sumario:Patient: Male, 58-year-old Final Diagnosis: Invasive cribriform carcinoma Symptoms: A painful and palpable enlarging breast mass Clinical Procedure: Adjuvant chemotherapy • surgery Specialty: Oncology OBJECTIVE: Rare disease BACKGROUND: Male breast cancer is a very rare disease that represents 0.6% of all breast carcinomas. Among breast carcinomas, invasive cribriform carcinoma (ICC) is a rare type of breast carcinoma and is more common in older women, with only a few cases in men reported. We present a case of male breast cancer with ICC. CASE REPORT: A 58-year-old man presented with a painful and palpable mass in the left breast, which was diagnosed as breast cancer of the ICC type. The patient underwent total mastectomy plus sentinel lymph node biopsy. On the microscope, the tumor was composed of more than 90% cribriform glands with comedo necrosis and dystrophic calcification. On immunohistochemical (IHC) staining, it appeared to be a luminal breast cancer. The IHC staining for c-erb B2 was equivocal (2 positive); hence fluorescence in situ hybridization was performed, and showed no amplification of the HER2/neu oncogene. The Ki-67 labeling index was 30%. The patient received radiotherapy and adjuvant systemic chemotherapy (4 cycles of docetaxel and cyclophosphamide), and has been on antiestrogen therapy (daily tamoxifen, 20 mg) for 30 months with no evidence of disease. CONCLUSIONS: ICC is a rare type of invasive carcinoma of the breast, and ICC from the male breast is extremely rare. We report, in this case, the final pathologic results of a male patient diagnosed with ICC breast cancer and treated with surgery, chemotherapy, and radiotherapy.